Casma to develop CSM-101 as treatment for Parkinson's
Casma Therapeutics will develop CSM-101 as a potential oral treatment for Parkinson's disease and Gaucher disease.| Parkinson's News Today
Casma Therapeutics will develop CSM-101 as a potential oral treatment for Parkinson's disease and Gaucher disease.| Parkinson's News Today
Cure Parkinson’s is funding SLEIPNIR, a clinical trial platform that will simultaneously test up to three disease-modifying treatments.| Parkinson's News Today
No description.| Parkinson's News Today
Parkinson's disease symptoms affect both motor skills and nonmotor skills, and progress differently in each person.| Parkinson's News Today
The causes of Parkinson's disease can include a combination of genetic and environmental factors. Age and gender may also be risk factors.| Parkinson's News Today
Category archive page for News.| Parkinson's News Today
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Parkinson's News Today
Learn about Parkinson's disease, a condition that affects the brain, resulting in issues with movement, balance, and more.| Parkinson's News Today
